LISATA THERAPEUTICS, INC. (LSTA)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue Annual

0 25M 50M 75M FY10: 69.8M FY11: 10.1M FY12: 14.3M FY13: 14.7M FY14: 17.9M FY15: 22.5M FY16: 35.3M FY22: 0 FY23: 0 FY24: 1M FY25: 170K FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY22 FY23 FY24 FY25

Gross Profit Annual

0 7M 14M 21M FY10: 20.2M FY11: 1.4M FY12: 2.4M FY13: 1.7M FY10 FY11 FY12 FY13

Operating Income Annual

-120M -80M -40M 0 40M 80M 120M FY10: -18.9M FY11: -34M FY12: -30.4M FY13: -36.8M FY14: -57.7M FY15: -113.8M FY16: -29.5M FY17: -27.6M FY18: -17M FY19: -20.1M FY20: -19.1M FY21: -29.1M FY22: -57.6M FY23: -25.7M FY24: -22.4M FY25: -18.2M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Net Income Annual

-90M -60M -30M 0 30M 60M 90M FY10: -23.3M FY11: -47.1M FY12: -53.8M FY13: -39M FY14: -54.9M FY15: -81M FY16: -32.7M FY17: 23M FY18: -16.2M FY19: -19.4M FY20: -8.2M FY21: -27.5M FY22: -54.2M FY23: -20.8M FY24: -20M FY25: -16.6M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Cost of Revenue Annual

0 20M 40M 60M FY10: 49.7M FY11: 8.6M FY12: 11.9M FY13: 12.9M FY14: 15.7M FY15: 20.2M FY16: 31.1M FY10 FY11 FY12 FY13 FY14 FY15 FY16

Operating Cash Flow Annual

-60M -40M -20M 0 20M 40M 60M FY10: -8.5M FY11: -20.9M FY12: -13.9M FY13: -27.1M FY14: -46.9M FY15: -39.3M FY16: -23.7M FY17: -20.9M FY18: -20M FY19: -18.9M FY20: -8.8M FY21: -22.2M FY22: -21.2M FY23: -20M FY24: -19.4M FY25: -15.9M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Free Cash Flow Annual

-60M -40M -20M 0 20M 40M 60M FY10: -24.9M FY11: -21.5M FY12: -14.4M FY13: -29.8M FY14: -50.6M FY15: -42.4M FY16: -24.8M FY17: -21M FY18: -20.1M FY19: -18.9M FY20: -8.8M FY21: -22.3M FY22: -21.5M FY23: -20M FY24: -19.4M FY25: -16M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 6M 12M 18M FY16: 6.5M FY17: 9M FY18: 9.7M FY20: 15.4M FY21: 3.7M FY22: 5.2M FY23: 8.1M FY24: 8.3M FY25: 8.7M FY16 FY17 FY18 FY20 FY21 FY22 FY23 FY24 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-15.00 -10.00 -5.00 0.00 5.00 10.00 15.00 Q4 '10: -0.46 Q1 '11: -0.48 Q2 '11: -0.50 Q3 '11: -0.45 Q4 '11: -0.54 Q1 '12: -0.48 Q2 '12: -1.88 Q3 '12: -2.44 Q4 '12: -3.24 Q1 '13: -3.69 Q2 '13: -2.62 Q3 '13: -2.43 Q4 '13: -1.91 Q1 '14: -1.87 Q2 '14: -1.81 Q3 '14: -1.84 Q4 '14: -1.69 Q1 '15: -1.71 Q2 '15: -5.15 Q3 '15: -6.73 Q4 '15: -7.00 Q1 '16: -8.58 Q2 '16: -6.07 Q3 '16: -5.10 Q4 '16: -5.05 Q1 '17: -4.08 Q2 '17: 1.59 Q3 '17: 2.30 Q4 '17: 2.56 Q1 '18: 3.16 Q2 '18: -1.60 Q3 '18: -1.58 Q4 '18: -1.66 Q1 '19: -1.58 Q2 '19: -1.65 Q3 '19: -1.76 Q4 '19: -1.88 Q1 '20: -1.82 Q2 '20: -0.83 Q3 '20: -0.65 Q4 '20: -0.51 Q1 '21: -0.32 Q2 '21: -0.92 Q3 '21: -2.37 Q4 '21: -3.72 Q1 '22: -4.58 Q2 '22: -6.12 Q3 '22: -12.26 Q4 '22: -10.47 Q1 '23: -10.19 Q2 '23: -9.05 Q3 '23: -1.82 Q4 '23: -2.58 Q1 '24: -2.46 Q2 '24: -2.57 Q3 '24: -2.51 Q4 '24: -2.40 Q1 '25: -2.30 Q2 '25: -2.23 Q3 '25: -2.13 Q4 '25: -1.91 Q1 '26: -1.86 Q2 '26: -1.64 Q2 '12 Q2 '14 Q2 '16 Q2 '18 Q2 '20 Q2 '22 Q2 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.